financetom
Business
financetom
/
Business
/
What's Going On With Stitch Fix Shares Wednesday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Stitch Fix Shares Wednesday?
Jun 11, 2025 1:20 PM

Stitch Fix, Inc. ( SFIX ) stock was trading higher but has since reversed and started to trade lower after the company reported better-than-expected third-quarter earnings on Tuesday, after the market closed.

What To Know: The company reported a loss of six cents per share, beating the consensus estimate of an 11 cent loss. In addition, Stitch Fix ( SFIX ) reported sales of $325.02 million, beating the consensus estimate of $314.44 million.

The company reported 2.35 million active clients, down 10.6% year-over-year, with net revenue per active client rising 3.2% to $542.

It ended the quarter with $242.1 million in cash, cash equivalents and investments.

“Stitch Fix delivered strong third quarter results, marked by our overall return to year-over-year revenue growth,” said Matt Baer, CEO, Stitch Fix ( SFIX ).

“Our performance, which exceeded expectations, is the direct result of the strength of the Stitch Fix ( SFIX ) value proposition and the team’s disciplined execution of our strategy. Now in the growth phase of our transformation, we are focused on cementing our role as the retailer of choice for apparel and accessories by consistently delivering the most client-centric and personalized shopping experience.”

Outlook: The company sees fourth-quarter sales from $298 million to $303 million, versus the consensus estimate of $288.57 million.

Stitch Fix ( SFIX ) now expects fiscal-year sales from $1.25 billion to $1.26 billion, versus the consensus estimate of $1.23 billion. The company previously expected sales form $1.23 billion to $1.24 billion.

Following the earnings report, Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating on Stitch Fix ( SFIX ) and maintained a $6 price target.

SFIX Price Action: Stitch Fix ( SFIX ) closed Wednesday 10.54% lower at $4.29, according to data from Benzinga Pro.

Related Link:

Palantir Powers Up: AI ETFs Ride The Rally, But At What Cost?

Image: This illustration was generated using artificial intelligence via Midjourney.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved